期刊文献+

异质性万古霉素耐药金黄色葡萄球菌的抗生素后效应

下载PDF
导出
摘要 目的了解异质性万古霉素耐药金黄色葡萄球菌(h-VRSA)对万古霉素的抗生素后效应(PAE)等药代动办学特点,探讨h—VRsA的存在,对万古霉素的杀菌活性及其临床应用方面的影响。方法分别检测ATCC 29213和h—VRSA(原代培养)的最低抑菌浓度(MIC).最低杀菌浓度(MBC)以及PAE。结果ATCC 29213的MIC和MBC分别为1ug/mL和16ug/mL,h--VRSA(原代)的MIC和MBC分别为2ug/mL和64ug/mLl两者PAE分别为0.9h和2.2h。结论与ATCC 29213不同,h--VRSA的PAE明显延长:MIC为2ug/mL的h—VRSA其MBC可以达到64ug/mL,已经高于万古霉素的有效血药浓度峰值(20~40)ug/mLl提示单独使用万古霉素已经不能完全清除h—vRsA。
出处 《中外医疗》 2008年第3期31-32,共2页 China & Foreign Medical Treatment
基金 苏州市科教兴卫青年基金资助(SWQ15)
  • 相关文献

参考文献1

二级参考文献24

  • 1CDC. Staphylococcus aureus resistant to Vancomycin-United States,2002. Morb Mortal Wkly Rep, 2002, 51(26): 565-567.
  • 2CDC. Public Health Dispatch: Vancoomycin-Resistant Staphylococcus aureusPennsylvania, 2002. Morb Mortal Wkly Rep, 2, 2002, 51(40): 902.
  • 3Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997, 40(1): 135-136.
  • 4Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet, 1997, 350(12): 1670-1673.
  • 5Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of Staphylococci. Antimicrob Agents Chemother, 1998, 42(1):100-107.
  • 6Marchese A, Balistreri G, Tonoli E, et al. Heterogeneous vancomycin resistance in mehthiillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital . J Clin Microbiol, 2000, 38(2): 866-869.
  • 7Poly MC, Grelaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Stsaphylococcus in a French hospital. Lancet, 1998,351: 1212.
  • 8Viedma DG, Rabadan PM, Diaz M, et al. Heterogeneous antimicrobial resistance patterns in polyclonal populations of coagulase-negative Staphylococcus isolated from catheters. J Clin Microbiol, 2000, 38(4): 1359-1363.
  • 9Wong SSY, Ho PL, Woo PCY, et al. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis, 1999,29: 760-767.
  • 10CDC. Investigation and Control of Vancomycin-Intermediate and resistant Staphylococcus aureus: A guide for health department and infection control personnel. Atlanta, GA. 2003 (Accessed at http://www. cdc.gov/ncidod/hip/ARESIST/visa-vrsa-guide. pdf)

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部